The MIR-study

 

MicroRNA is promising as a biomarker in germ cell tumors.

The SWENOTECA MIR-study consists of several modules: 

 

Module1. Determine miRs before and after orchiectomy with one sample before and three measurements the days after orchiectomy to determine the half life.

 

Module 2. Use miRs to determine tumour response to chemotherapy and aid in decisions on treatment intensification or stopping therapy in testicular cancer patients with metastases.

 

Module 3. Assess the value of miRs to detect early recurrences after initial staging and therapy.

 

Module 4. Determine the clinical role of tissue markers in primary testicular cancer tissues.

 

Module 5 Determine normal levels of relevant miRs in control men

 

Module 6 Korrelation of markers detected with GWAS studies with the clinical presentation (stage)  and prognosis (respons to chemotherapy and recurrence)

 

All patients with germ cell tumors can be included. patients can be included in several clinical settings.

  • Before orchiectomy

  • At staging/before adjuvant chemotherapy

  • Before treatment of metastatic disease

 

Questions regarding the study can be directed to Olav Dahl

 

Sponsor: Haukeland University Hospital, Bergen, Norway

Primary Investigator: Olav Dahl

 

 

 

 

 

​​​Contact Us

SWENOTECA

Kreftklinikken, St. Olavs Hospital,

Postboks 3250 Sluppen

7006 Trondheim, Norway

Follow Us

  • w-facebook

swenoteca.org

 © 2015 SWENOTECA